Lifeboat Foundation

Dr. Aubrey de Grey from the SENS Research Foundation was kind enough to talk in support of CellAge and their campaign on Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

Continue reading “CellAge: Dr. Aubrey de Grey Endorsement Video” »

Cellular senescence is a complicated process but here it is explained in a simple infographic. The removal of senescent cells (senolytics) is a very hot topic right now and it represents the arrival of the first of the SENS therapies.

CellAge is one of the companies engaged in senolytic research and they are running a campaign on Lifespan.io if you would like to learn more about them.

https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/

Continue reading “Senescent cells accumulate with age and gradually poison their neighboring cells and secrete signals that shut down your stem cells and reduce your ability to regenerate tissue” »

Are you an avid supporter of aging research and a keen longevity activist?
The Biogerontology Research Foundation is offering select summer internships for talented individuals. You’d join a passionate and supportive team in researching diagnostic, prognostic, and therapeutic strategies; advising a panel of investors in developing a roadmap to promote longevity science and related technologies across the globe.

The advertised positions are 3 month internships, with the possibility of continuing afterwards. Free accommodation will be provided for in London, alongside a negotiable salary.

The Biogerontology Research Foundation is a UK based think tank dedicated to aging research and accelerating its application worldwide.

Continue reading “Aging Research Internships Available 6” »

Not posting for any political reasons. Only to show that this guy who is firmly behind Anti Aging tech will be a close adviser to the next President.

Peter Thiel, the billionaire venture capitalist and conservative libertarian, has long been a misfit in Silicon Valley.

Now as one of the tech industry’s main bridges to President-elect Donald Trump’s incoming administration, Mr. Thiel is playing a central role in helping shape the relationship with a president most tech titans didn’t want.

Continue reading “Investor Peter Thiel Is Helping Mold Tech’s Ties to Donald Trump” »

Progress with Alzheimers and this time approaching it from the direction of Tau as a target rather than Beta Amyloid. This therapy has been tested in people and whilst it is only the first step hopefully this will lead to an effective treatment for this horrific diseases and and end to the suffering it brings.

Progress towards immunotherapies that can clear tau for Alzheimers here. Most therapies are focused on misfolded amyloid-β proteins but this particular approach targets Tau and the first in human test has proceeded!

“The authors of the study have developed a vaccine that stimulates the production of an antibody that specifically targets pathological tau, discovering its “Achilles’ heel”. It is able to do this because healthy tau undergoes a series of changes to its structure forming a new region that the antibody attacks. This new region (the “Achilles’ heel”), while not present in healthy tau, is present in diseased tau early on. Therefore, the antibody tackles all the different varieties of pathological tau. In addition to this important specificity, the antibody is coupled to a carrier molecule that generates a considerable immune response with the added benefit that it is not present in humans, thus avoiding the development of an immune reaction towards the body itself.”

#aging #crowdfundthecure

Removing Glucosepane crosslinks from tissue is one of the most important things groups like SENS Research Foundation are doing and their progress relies on our support.

In this interesting open access paper, the authors propose that too little attention has been given to immune cell behavior in tissues rather than in blood, and that means that researchers have overlooked the possibility that age-related changes in the extracellular matrix structures that support tissues might be a significant cause of the growing immune dysfunction that takes place in later life. One of the more important of these changes in the extracellular matrix is the growing presence of cross-links, persistent sugary compounds produced as a byproduct of normal metabolic operations that chain together the large molecules of the extracellular matrix. In doing so these cross-links change the chemical and structural properties of the matrix and the tissue as a whole, producing results such as loss of elasticity in skin and blood vessels, which in turn contribute to a variety of age-related diseases. If cross-linking does indeed contribute to immunosenescence, the decline of the immune system with age, then that only increases the importance of ongoing research funded by the SENS Research Foundation aimed at safely breaking down this unwanted form of metabolic waste. In humans near all persistent cross-links appear to involve a single class of compound, glucosepane. So in theory there is only a single target here, needing just one drug development program to make a large difference to long-term health and longevity.

Determining brain age from an MRI scan has always been a time-consuming business. Now an AI machine gives the answer in seconds.

You have the power to change the future of medicine and how we treat age-related diseases. Here is an example of how grassroots fundraising is changing science.

Joining the circulatory system of an old with a young animal has been shown to rejuvenate old tissues. Here the authors describe a comparatively simple blood infusion system that allows for the controlled exchange of blood between two animals, and study the effects of a single exchange on various tissues.

The CellAge AMA is open for questions, come along and ask about biotechnology, senolytics and so on.

Welcome to the CellAge AMA with Mantas Matjusaitis, PhD student in synthetic biology and founder of CellAge. I am here to talk about our work to improve the targeting of dysfunctional “senescent” cells in the body, and thereby aid in their eventual removal. This is important because removal of these cells has been shown to be a critical component in the effort to improve healthy human lifespan.

In short, CellAge is going to develop synthetic DNA promoters which are specific to senescent cells, as the promoters that are currently used for this purpose, such as the p16 gene promoter, suffer from various issues and limitations (not comprehensively targeting all senescent cells, collateral damage in targeting some cells that are not senescent, etc.). You can find more details in our technology video here, and on our Lifespan.io information page.

Continue reading “CellAge AMA: Targeting Senescent Cells with Synthetic Biology for Human Longevity : Futurology” »